Sciomics established a broad biomarker development pipeline for oncological indications as well as organ failure. The underlying scioDiscover platform combines a broad coverage of more than 1000 proteins including their phosphorylation status with all advantages of classical immunoassays.
Plasma, tissue, cell samples, and cerebrospinal fluid from human, mice and rat can be analysed to identify biomarkers, elucidate disease mechanisms or obtain an in-depth understanding of the underlying biology